The Potential Use of Catalytic RNAs in Therapy of HIV Infection and Other Diseases
Overview
Authors
Affiliations
This article describes the applications (both real and potential) of a new antiviral strategy, based on the use of antisense, catalytic RNAs (ribozymes) as therapeutic agents. An understanding of both antisense inhibition of gene expression and RNA autocleavage reactions are essential to the use of this technology. In addition, for the successful application of this technology in clinical settings, an interdisciplinary approach involving clinicians, molecular and cellular biologists, will be necessary. The following treatise will highlight several salient features of ribozyme technology, emphasizing its application as an antiviral as well as discuss some problems and potential solutions pertinent to the clinical application of this technology.
Digitizable therapeutics for decentralized mitigation of global pandemics.
Hacohen A, Cohen R, Efroni S, Barzel B, Bachelet I Sci Rep. 2019; 9(1):14345.
PMID: 31586137 PMC: 6778202. DOI: 10.1038/s41598-019-50553-x.
Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme.
Yokoyama Y, Morishita S, Takahashi Y, Hashimoto M, Tamaya T Br J Cancer. 1997; 76(8):977-82.
PMID: 9376277 PMC: 2228084. DOI: 10.1038/bjc.1997.496.
Gu J, Nadler J, Rossi J Mol Cell Biochem. 1997; 172(1-2):47-57.
PMID: 9278231
Sun L, Ely J, GERLACH W, Symonds G Mol Biotechnol. 1997; 7(3):241-51.
PMID: 9219238 DOI: 10.1007/BF02740815.
Sun L, Warrilow D, Wang L, Witherington C, MacPherson J, Symonds G Proc Natl Acad Sci U S A. 1994; 91(21):9715-9.
PMID: 7937878 PMC: 44887. DOI: 10.1073/pnas.91.21.9715.